E-18 Corp. Announces Availability of a White Paper by SmallcapInsights.com
MINNEAPOLIS-(Business Wire)-September 10, 2009 - E-18 Corp. (OTCBB:ETEN), through its wholly owned subsidiary, SquareOne Medical, Inc., doing business as Protectus Medical Devices ("Protectus Medical Devices"), today announces the release of a white paper on the global market for safety syringes by the editors of SmallcapInsights.com.
Entitled “Preventing Needlestick Injury: The Global Market for Safety Syringes”, the white paper details the significant exposure healthcare workers face from needlestick injuries, the structure and size of the overall syringe market, as well as how ‘self-sheathing’ safety syringes are being demanded by doctors and nurses on the front lines to curb accidental injuries.
From the white paper, “The World Health Organization estimates that nearly three million healthcare workers worldwide are exposed to blood-borne diseases in the course of their work every year, resulting in as many as 70,000 hepatitis B infections, 15,000 hepatitis C infections and 500 HIV infections per year.”
The paper goes on to say, “These injuries are both dangerous and quite costly. The American Hospital Association estimates average treatment cost per needlestick injury at $450-800, even if there is no transmission of disease; up to $3,000 if there is a minor infection; and up to $1 million if the needlestick results in a serious infection.”
Developed by Protectus Medical Devices, the Protectus Safety Syringe has the potential to revolutionize this segment of the healthcare system as the only safety syringe in the world that automatically self-sheaths and meets every requirement of the OSHA mandates passed by the U.S. Federal Government.
“As this white paper effectively illustrates, accidental needlestick injuries occurring in our healthcare system take a massive toll on our society, in both monetary and human terms,” remarks Dr. John Salstrom, President and CEO of Protectus Medical Devices. “Fortunately, a truly automatic self-sheathing device, like the Protectus Safety Syringe, could significantly reduce or eliminate the number of accidental needlestick cases each year, and thus save billions of dollars in injuries and potentially hundreds of lives.”
A link to the white paper is available on the SmallcapInsights.com website: http://www.smallcapinsights.com.
About E-18 Corp.
E-18 Corp., through its wholly owned subsidiary, SquareOne Medical, Inc., doing business as Protectus Medical Devices, develops and markets innovative safety medical percutaneous devices that, collectively, have the potential to dramatically reduce needlestick injuries for medical professionals worldwide. In the nearly $5 billion global hypodermic syringe market, the Protectus Safety Syringe, the Company's lead product, is the only fully automatic, self-sheathing hypodermic safety syringe that currently meets the functional definition of "Self-Sheathing" mandated by the U.S. Federal Government. None of the manufacturers of other devices on the market can make this claim. Protectus Medical Devices has successfully patented its automatic, self-sheathing hypodermic safety syringe product, and, based on the results of full comparison clinical trials, the Protectus Safety Syringe (formerly the SquareOne Safety Syringe) has received the required 510(k) permission from the U.S. FDA to manufacture and market the device in the U.S. More information about the Company may be found at www.protectusmedical.com.
Forward-Looking Statements
Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the Company's expectations with regard to the future impact on the Company's results from new products in development are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are subject to risks and uncertainties. Words such as "expects," "intends," "plans," "may," "could," "should," "anticipates," "likely," "believes" and words of similar import also identify forward-looking statements. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Readers are urged not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. Additional information on risks and other factors that may affect the business and financial results of E-18 Corp. can be found in the filings of E-18 Corp. with the U.S. Securities and Exchange Commission.
SEC Section 17(b) Disclosure: SmallcapInsights.com is a wholly owned subsidiary of Trilogy Capital Partners, Inc. (“Trilogy”). Trilogy has been engaged by E-18 Corp. ("ETEN") to provide investor relations services for compensation including a monthly retainer of $10,000 for an initial twelve month term and 450,000 shares of restricted common stock of ETEN, to be distributed in equal monthly installments over a six month period.
 |
 |
 |
|
||
 |
|
 |
|
||
Search Our News Using Google Search
Can't find what you want? Try using Google:
